Pharmacovigilance and Safety Reporting to DAV in 2025


Pharmacovigilance and Safety Reporting to DAV in 2025

Published on 22/12/2025

Pharmacovigilance and Safety Reporting to DAV in 2025

As the landscape of pharmaceutical regulation evolves, maintaining compliance with pharmacovigilance and safety reporting requirements is crucial, particularly for entities operating in Vietnam. The Drug Administration of Vietnam (DAV) serves as the authoritative body overseeing regulatory compliance, including drug registration and pharmacovigilance processes. This article provides a comprehensive step-by-step tutorial on the pharmacovigilance and safety reporting requirements to the DAV in 2025, catering specifically to professionals in regulatory affairs, quality assurance, clinical trials and market access.

Step 1: Understanding the Regulatory Framework

Before initiating the pharmacovigilance and safety reporting process, it is essential to understand the regulatory framework in Vietnam. The key legislation governing pharmacovigilance includes the Law on Pharmacy, which outlines responsibilities for drug safety, and corresponding Decrees and Circulars from the Ministry of Health.

The DAV, as a part of the Ministry of Health, is responsible for monitoring adverse drug reactions (ADRs) and ensuring the safety of medicinal products. Familiarize

yourself with the following resources to gain a clearer understanding:

  • Law on Pharmacy: This lays out the fundamental principles of drug management, including pharmacovigilance.
  • Decree No. 54/2017/ND-CP: Details regulations on pharmaceutical business activities, including safety reporting.
  • Circular No. 29/2018/TT-BYT: Provides guidance on the establishment and management of pharmacovigilance systems.

Understanding these laws and regulations will help ensure your organization’s pharmacovigilance system aligns with the requirements laid out by the DAV. It is also advisable to appoint a pharmacovigilance officer within your organization to oversee compliance and report any safety concerns effectively.

Step 2: Setting Up a Pharmacovigilance System

Establishing a robust pharmacovigilance system is essential for effective monitoring of drug safety. A pharmacovigilance system must encompass various elements, including the collection, management, and evaluation of safety data. Here are the steps to set up an effective pharmacovigilance system:

Also Read:  Swissmedic Requirements for Biologics and Biosimilars in 2025

Define Roles and Responsibilities

Clearly define the roles and responsibilities of team members involved in the pharmacovigilance process. Key roles typically include:

  • Pharmacovigilance Officer: Oversees the entire pharmacovigilance system.
  • Data Entry Personnel: Responsible for entering ADR data into the system.
  • Quality Assurance Specialist: Ensures compliance with regulatory guidelines.

Develop Standard Operating Procedures (SOPs)

Create detailed SOPs for all aspects of pharmacovigilance, including:

  • Reporting mechanisms for ADRs
  • Data collection and management
  • Regular audits and quality checks

Implement a Data Management System

Choose a validated data management system (DMS) that is compliant with Vietnamese regulations. The system should be capable of:

  • Collecting safety data from various sources
  • Tracking and managing ADR reports
  • Generating reports for submission to the DAV

Training staff on the use of the DMS is equally crucial. This will ensure accurate data collection and entry, leading to comprehensive safety reporting.

Step 3: Safety Data Collection and Reporting

After establishing a pharmacovigilance system, the next step is to collect and report safety data. This involves various components, such as identifying adverse drug reactions (ADRs) and understanding reporting timelines and requirements.

Identification of Adverse Drug Reactions (ADRs)

ADRs can arise from various sources, including clinical trials, post-marketing surveillance, and spontaneous reports from healthcare professionals or patients. It is essential to cultivate an environment where staff and healthcare professionals feel empowered to report any incidents involving ADRs.

Establish Reporting Timelines

The DAV requires timely reporting of serious ADRs, typically within 15 days of identification. Other non-serious ADRs should be reported at least annually. It is important to adhere to these timelines to remain compliant with Vietnamese regulations.

Documenting Adverse Events

When documenting ADRs, ensure the following data points are collected:

  • Patient details (without compromising confidentiality)
  • Drug name, dosage, and administration route
  • Details of the adverse event
  • The outcome and action taken
Also Read:  Clinical Trial Authorization Process Under BPOM Indonesia in 2025

All records should be kept in a secure and organized manner. This facilitates easy access and review during audits or inspections.

Step 4: Submission of Safety Reports to DAV

Once safety data is compiled, timely submission to the DAV is the next major step. The submission process involves specific formats, timelines, and documentation requirements.

Prepare the Safety Report

The safety report must be prepared in accordance with the guidelines set forth by the DAV. Typical reports include:

  • Individual Case Safety Reports (ICSRs)
  • Periodic Safety Update Reports (PSURs)
  • Annual Reports on pharmacovigilance activities

Submission Channels

Reports should be submitted through the DAV’s official channels. Ensure that you define the method of submission (electronic or paper). If submitting electronically, verify that your organization complies with DAV’s e-reporting system requirements.

Monitor and Address Feedback

After submission, monitor for any feedback from the DAV. They may request additional information or clarification. It’s important to address these inquiries promptly to maintain good standing with regulatory authorities.

Step 5: Post-Approval Commitments and Continuous Monitoring

Once a drug receives market authorization, the responsibilities do not cease. Ongoing monitoring and post-approval commitments are vital to ensure the safety and efficacy of the drug throughout its lifecycle.

Implement Post-Marketing Surveillance

Conduct post-marketing surveillance to continue monitoring the safety profile of the drug. This may include:

  • Long-term studies to observe ongoing effects
  • Surveys of healthcare professionals and patients
  • Review of additional spontaneous ADR reports

Periodic Safety Update Reports (PSURs)

Institutions must submit PSURs to the DAV regularly. These reports summarize safety data and the ongoing safety evaluation of the drug, typically on a yearly basis. Each PSUR must provide:

  • A cumulative safety data overview
  • Changes to the current safety assessment
  • Proposed descriptive actions if necessary

Engage with Stakeholders

Maintaining open lines of communication with stakeholders, including healthcare providers, patients, and regulatory authorities is critical. Engaging stakeholders allows for better visibility into potential safety concerns and reinforces trust in your organization.

Also Read:  CPR Application Requirements for Pharmaceutical Products in 2025

Conclusion and Best Practices

Compliance with pharmacovigilance and safety reporting requirements to the DAV in Vietnam is essential for the success of pharmaceutical products in the market. By implementing a robust pharmacovigilance system, establishing standard operating procedures, and maintaining full transparency with the DAV, organizations can foster safe drug usage and adherence to regulations.

Remember that each of these steps requires meticulous attention to detail and strict adherence to local regulations. By embracing these practices, your organization can effectively navigate the complexities offered by the regulatory landscape in Vietnam.